Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Envista Holdings Corporation is a medical instruments & supplies business based in the US. Envista Holdings Corporation shares (NVST) are listed on the NYSE and all prices are listed in US Dollars.
|52-week range||USD$10.08 - USD$41.4|
|50-day moving average||USD$36.8367|
|200-day moving average||USD$29.5677|
|Wall St. target price||USD$45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.598|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Envista Holdings Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Envista Holdings Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Envista Holdings Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Envista Holdings Corporation shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Envista Holdings Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$345.4 million.
The EBITDA is a measure of a Envista Holdings Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$2.3 billion|
|Operating margin TTM||9.33%|
|Gross profit TTM||USD$1.2 billion|
|Return on assets TTM||2.04%|
|Return on equity TTM||0.92%|
|Market capitalisation||USD$6.1 billion|
TTM: trailing 12 months
There are currently 10.5 million Envista Holdings Corporation shares held short by investors – that's known as Envista Holdings Corporation's "short interest". This figure is 12.6% down from 12.1 million last month.
There are a few different ways that this level of interest in shorting Envista Holdings Corporation shares can be evaluated.
Envista Holdings Corporation's "short interest ratio" (SIR) is the quantity of Envista Holdings Corporation shares currently shorted divided by the average quantity of Envista Holdings Corporation shares traded daily (recently around 1.5 million). Envista Holdings Corporation's SIR currently stands at 7.2. In other words for every 100,000 Envista Holdings Corporation shares traded daily on the market, roughly 7200 shares are currently held short.
However Envista Holdings Corporation's short interest can also be evaluated against the total number of Envista Holdings Corporation shares, or, against the total number of tradable Envista Holdings Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Envista Holdings Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Envista Holdings Corporation shares in existence, roughly 70 shares are currently held short) or 0.0829% of the tradable shares (for every 100,000 tradable Envista Holdings Corporation shares, roughly 83 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Envista Holdings Corporation.
Find out more about how you can short Envista Holdings Corporation stock.
We're not expecting Envista Holdings Corporation to pay a dividend over the next 12 months.
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures and markets dental products in the United States and internationally. The company operates in two segment, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare systems, Alpha Bio Tec, Implant Direct, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Pelton & Crane, Kerr, MetrexTM, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.